Literature DB >> 18406086

Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.

Ariella Shikanov1, Sergey Shikanov, Boris Vaisman, Jacob Golenser, Abraham J Domb.   

Abstract

PURPOSE: The aim of this study was to investigate the effectiveness of paclitaxel controlled release from intratumorally injected polymer.
METHODS: The effectiveness of paclitaxel-polymer formulation injected intratumorally was tested in mouse bladder tumor model. To determine paclitaxel biodistribution in tumor at predetermined time periods the tumor was excised, frozen and sectioned, and the paclitaxel concentrations were determined in the tumor tissue and in plasma by HPLC. Histopathological evaluation of the necrosis and inflammation was performed on tumor sections.
RESULTS: In the paclitaxel/polymer group mice were injected intratumorally with 0.2 ml of the 10% (w/w) paclitaxel formulation, the tumor disappeared completely 5 days after injection, and mice survived till the end of the study (50 days post-tumor cells inoculation). In biodistribution studies, the highest paclitaxel concentration in the tumor tissue was 40 microg/mg 1 day after the intratumoral injection and decreased gradually during 10 days to 5 microg/mg that is still high enough to induce cytotoxic effect, and the necrotic effect of paclitaxel on the tumors was confirmed by histopathology.
CONCLUSIONS: Treatment with local injection of polymer-paclitaxel formulation inhibited the growth of solid tumors. Distribution studies of paclitaxel after intratumoral injection showed high and effective drug concentrations in tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406086     DOI: 10.1016/j.ijpharm.2008.02.028

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  In vivo screening of S100B inhibitors for melanoma therapy.

Authors:  Danna B Zimmer; Rena G Lapidus; David J Weber
Journal:  Methods Mol Biol       Date:  2013

2.  Local controlled delivery of anti-neoplastic RNAse to the brain.

Authors:  Joram Slager; Betty Tyler; Ariella Shikanov; Abraham J Domb; Kuslima Shogen; David Sidransky; Henry Brem
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

3.  Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies.

Authors:  Shufang Nie; W L Wendy Hsiao; Weisan Pan; Zhijun Yang
Journal:  Int J Nanomedicine       Date:  2011-01-19

4.  Cisplatin tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.

Authors:  Ariella Shikanov; Sergey Shikanov; Boris Vaisman; Jacob Golenser; Abraham J Domb
Journal:  Chemother Res Pract       Date:  2011-02-27

5.  Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles.

Authors:  Aaron H Colby; Rong Liu; Morgan D Schulz; Robert F Padera; Yolonda L Colson; Mark W Grinstaff
Journal:  Sci Rep       Date:  2016-01-07       Impact factor: 4.379

6.  Non-covalent assembly of meso-tetra-4-pyridyl porphine with single-stranded DNA to form nano-sized complexes with hydrophobicity-dependent DNA release and anti-tumor activity.

Authors:  Supratim Ghosh; Kamil B Ucer; Ralph D'Agostino; Ken Grant; Joseph Sirintrapun; Michael J Thomas; Roy Hantgan; Manish Bharadwaj; William H Gmeiner
Journal:  Nanomedicine       Date:  2013-08-27       Impact factor: 5.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.